Cargando…
Cemiplimab in Ultra-Octogenarian Patients with Cutaneous Squamous Cell Carcinoma: The Real-Life Experience of a Tertiary Referral Center
Background: The incidence of cutaneous squamous cell carcinoma (cSCC) is rapidly increasing, paralleling the aging of the population. cSCC predominantly affects chronically sun-exposed areas, such as the head and neck region. At our tertiary center, a multidisciplinary approach to non-melanoma skin...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10534594/ https://www.ncbi.nlm.nih.gov/pubmed/37766176 http://dx.doi.org/10.3390/vaccines11091500 |
_version_ | 1785112431269249024 |
---|---|
author | Denaro, Nerina Passoni, Emanuela Indini, Alice Nazzaro, Gianluca Beltramini, Giada Anna Benzecry, Valentina Colombo, Giuseppe Cauchi, Carolina Solinas, Cinzia Scartozzi, Mario Marzano, Angelo Valerio Garrone, Ornella |
author_facet | Denaro, Nerina Passoni, Emanuela Indini, Alice Nazzaro, Gianluca Beltramini, Giada Anna Benzecry, Valentina Colombo, Giuseppe Cauchi, Carolina Solinas, Cinzia Scartozzi, Mario Marzano, Angelo Valerio Garrone, Ornella |
author_sort | Denaro, Nerina |
collection | PubMed |
description | Background: The incidence of cutaneous squamous cell carcinoma (cSCC) is rapidly increasing, paralleling the aging of the population. cSCC predominantly affects chronically sun-exposed areas, such as the head and neck region. At our tertiary center, a multidisciplinary approach to non-melanoma skin cancer is provided for locally advanced cSCC. Methods: We retrospectively revised all patients with locally advanced/metastatic cSCC treated with anti-PD1 antibody (Cemiplimab) at our Institution from January 2020 to March 2023 (minimum follow-up of 4 months on treatment). Results: Overall, we consecutively treated 20 ultra-octogenarian patients, of whom 15 were males and 5 were females (median age: 86.9 years). Despite age, a median number of concomitant drugs, and comorbidities, efficacy, and safety were superimposable with the available literature. No patients reported treatment-related adverse events of grade 3 or higher. Grade 2 adverse events were reported in 25% of patients. Overall, the response rate was 65%, with 50% partial responses and 20% long-lasting stable disease. The median duration of response was 14 months. The G8 elderly score was assessed in all patients, and the median score was 12 (range 9–14). Conclusions: Among ultra-octogenarian patients, a clinical benefit from Cemiplimab was obtained in most, including tumor shrinkage and pain relief. Cemiplimab confirmed its effectiveness in elderly patients in a real-life setting, with no new safety concerns. |
format | Online Article Text |
id | pubmed-10534594 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-105345942023-09-29 Cemiplimab in Ultra-Octogenarian Patients with Cutaneous Squamous Cell Carcinoma: The Real-Life Experience of a Tertiary Referral Center Denaro, Nerina Passoni, Emanuela Indini, Alice Nazzaro, Gianluca Beltramini, Giada Anna Benzecry, Valentina Colombo, Giuseppe Cauchi, Carolina Solinas, Cinzia Scartozzi, Mario Marzano, Angelo Valerio Garrone, Ornella Vaccines (Basel) Article Background: The incidence of cutaneous squamous cell carcinoma (cSCC) is rapidly increasing, paralleling the aging of the population. cSCC predominantly affects chronically sun-exposed areas, such as the head and neck region. At our tertiary center, a multidisciplinary approach to non-melanoma skin cancer is provided for locally advanced cSCC. Methods: We retrospectively revised all patients with locally advanced/metastatic cSCC treated with anti-PD1 antibody (Cemiplimab) at our Institution from January 2020 to March 2023 (minimum follow-up of 4 months on treatment). Results: Overall, we consecutively treated 20 ultra-octogenarian patients, of whom 15 were males and 5 were females (median age: 86.9 years). Despite age, a median number of concomitant drugs, and comorbidities, efficacy, and safety were superimposable with the available literature. No patients reported treatment-related adverse events of grade 3 or higher. Grade 2 adverse events were reported in 25% of patients. Overall, the response rate was 65%, with 50% partial responses and 20% long-lasting stable disease. The median duration of response was 14 months. The G8 elderly score was assessed in all patients, and the median score was 12 (range 9–14). Conclusions: Among ultra-octogenarian patients, a clinical benefit from Cemiplimab was obtained in most, including tumor shrinkage and pain relief. Cemiplimab confirmed its effectiveness in elderly patients in a real-life setting, with no new safety concerns. MDPI 2023-09-18 /pmc/articles/PMC10534594/ /pubmed/37766176 http://dx.doi.org/10.3390/vaccines11091500 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Denaro, Nerina Passoni, Emanuela Indini, Alice Nazzaro, Gianluca Beltramini, Giada Anna Benzecry, Valentina Colombo, Giuseppe Cauchi, Carolina Solinas, Cinzia Scartozzi, Mario Marzano, Angelo Valerio Garrone, Ornella Cemiplimab in Ultra-Octogenarian Patients with Cutaneous Squamous Cell Carcinoma: The Real-Life Experience of a Tertiary Referral Center |
title | Cemiplimab in Ultra-Octogenarian Patients with Cutaneous Squamous Cell Carcinoma: The Real-Life Experience of a Tertiary Referral Center |
title_full | Cemiplimab in Ultra-Octogenarian Patients with Cutaneous Squamous Cell Carcinoma: The Real-Life Experience of a Tertiary Referral Center |
title_fullStr | Cemiplimab in Ultra-Octogenarian Patients with Cutaneous Squamous Cell Carcinoma: The Real-Life Experience of a Tertiary Referral Center |
title_full_unstemmed | Cemiplimab in Ultra-Octogenarian Patients with Cutaneous Squamous Cell Carcinoma: The Real-Life Experience of a Tertiary Referral Center |
title_short | Cemiplimab in Ultra-Octogenarian Patients with Cutaneous Squamous Cell Carcinoma: The Real-Life Experience of a Tertiary Referral Center |
title_sort | cemiplimab in ultra-octogenarian patients with cutaneous squamous cell carcinoma: the real-life experience of a tertiary referral center |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10534594/ https://www.ncbi.nlm.nih.gov/pubmed/37766176 http://dx.doi.org/10.3390/vaccines11091500 |
work_keys_str_mv | AT denaronerina cemiplimabinultraoctogenarianpatientswithcutaneoussquamouscellcarcinomathereallifeexperienceofatertiaryreferralcenter AT passoniemanuela cemiplimabinultraoctogenarianpatientswithcutaneoussquamouscellcarcinomathereallifeexperienceofatertiaryreferralcenter AT indinialice cemiplimabinultraoctogenarianpatientswithcutaneoussquamouscellcarcinomathereallifeexperienceofatertiaryreferralcenter AT nazzarogianluca cemiplimabinultraoctogenarianpatientswithcutaneoussquamouscellcarcinomathereallifeexperienceofatertiaryreferralcenter AT beltraminigiadaanna cemiplimabinultraoctogenarianpatientswithcutaneoussquamouscellcarcinomathereallifeexperienceofatertiaryreferralcenter AT benzecryvalentina cemiplimabinultraoctogenarianpatientswithcutaneoussquamouscellcarcinomathereallifeexperienceofatertiaryreferralcenter AT colombogiuseppe cemiplimabinultraoctogenarianpatientswithcutaneoussquamouscellcarcinomathereallifeexperienceofatertiaryreferralcenter AT cauchicarolina cemiplimabinultraoctogenarianpatientswithcutaneoussquamouscellcarcinomathereallifeexperienceofatertiaryreferralcenter AT solinascinzia cemiplimabinultraoctogenarianpatientswithcutaneoussquamouscellcarcinomathereallifeexperienceofatertiaryreferralcenter AT scartozzimario cemiplimabinultraoctogenarianpatientswithcutaneoussquamouscellcarcinomathereallifeexperienceofatertiaryreferralcenter AT marzanoangelovalerio cemiplimabinultraoctogenarianpatientswithcutaneoussquamouscellcarcinomathereallifeexperienceofatertiaryreferralcenter AT garroneornella cemiplimabinultraoctogenarianpatientswithcutaneoussquamouscellcarcinomathereallifeexperienceofatertiaryreferralcenter |